KINASERA® Streptokinase 750,000 IU | Libya (BAYADERCARE)
KINASERA supports healthcare providers in Libya with reliable thrombolytic therapy
Streptokinase 750,000 IU Injection | BAYADERCARE Libya
Controlled thrombolytic therapy plays a vital role in the management of acute thrombotic conditions, particularly in clinical scenarios where gradual and closely monitored clot dissolution is required. Fibrinolytic agents are essential in supporting safe and effective restoration of blood flow in specialized treatment protocols.
|
KINASERA® 750,000 IU (Streptokinase Vial Injection) is a thrombolytic therapy designed for controlled fibrinolysis in clinical settings. It works by activating plasminogen to plasmin, leading to the breakdown of fibrin clots and restoration of blood flow.
|
| Applications / Uses: |
| Pulmonary Embolism (PE) |
| Deep Vein Thrombosis (DVT) |
| Arterial thrombosis |
| Controlled thrombolytic therapy |
| Hospital-based fibrinolytic protocols |
FAQ
Is KINASERA 750,000 IU available in Libya?
Yes, it is available through BAYADERCARE across Libya.
What is it used for?
| Controlled thrombolytic therapy in conditions such as PE and DVT. |
Where is it used?
| Hospitals, emergency units, and specialized care centers. |